590 reports of this reaction
1.3% of all EMTRICITABINE AND TENOFOVIR ALAFENAMIDE reports
#19 most reported adverse reaction
ECONOMIC PROBLEM is the #19 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 590 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE to ECONOMIC PROBLEM. This represents approximately 1.3% of all 46,639 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE who experience economic problem should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ECONOMIC PROBLEM is a less commonly reported adverse event for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, but still significant enough to appear in the safety profile.
In addition to economic problem, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE:
The following drugs have also been linked to economic problem in FDA adverse event reports:
ECONOMIC PROBLEM has been reported as an adverse event in 590 FDA reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ECONOMIC PROBLEM accounts for approximately 1.3% of all adverse event reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, making it a notable side effect.
If you experience economic problem while taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.